Haemolytic anaemia

References

Key articles

Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1;129(22):2971-9 Abstract

Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 Dec 1;106(12):3699-709.Full text  Abstract

Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005 Jul;42(3):137-44. Abstract

Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005 Aug 4;353(5):498-507. Abstract

Reference articles

1. Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009 May-Jun;42(3):267-78.Full text  Abstract

2. Beutler E. Red cell enzyme defects. Hematol Pathol. 1990;4(3):103-14. Abstract

3. Heller P, Best WR, Nelson RB, et al. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med. 1979 May 3;300(18):1001-5. Abstract

4. Prchal JT, Gregg XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program. 2005 Jan 1;1:19-23.Full text  Abstract

5. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002 Apr;69(4):258-71.Full text  Abstract

6. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017 Jun 1;129(22):2971-9 Abstract

7. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009 Jan 1;1:73-9.Full text  Abstract

8. Laurence J, Wong JE, Nachman R. The cellular hematology of systemic lupus erythematosus. In: Lahita RG, ed. Systemic lupus erythematosus. 2nd ed. New York, NY: Churchill Livingstone; 1992.

9. Wu Y, Perrotta PL, Snyder EL. Hematopoietic therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 7th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005:2402.

10. Giannini S, Martes C. Anemia in inflammatory bowel disease. Minerva Gastroenterol Dietol. 2006 Sep;52(3):275-91. Abstract

11. Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol. 1998 Feb;25(1):80-97. Abstract

12. Sallah S, Sigounas G, Vos P, et al. Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance. Ann Oncol. 2000 Dec;11(12):1571-7.Full text  Abstract

13. Hoffman PC. Immune hemolytic anemia - selected topics. Hematology Am Soc Hematol Educ Program. 2006 Jan 1;1:13-8.Full text  Abstract

14. Ismeno G, Renzulli A, Carozza A, et al. Intravascular hemolysis after mitral and aortic valve replacement with different types of mechanical prosthesis. Int J Cardiol. 1999 May 15;69(2):179-83. Abstract

15. Brown MR, Hasaniya NW, Dang CR. Hemolytic anemia secondary to a porcine mitral prosthetic valve leaflet dissection. Ann Thor Surg. 1995 Jun;59(6):1573-4. Abstract

16. Enzenauer RJ, Berenberg JL, Cassell PF Jr. Microangiopathic hemolytic anemia as the initial manifestation of porcine valve failure. South Med J. 1990 Aug;83(8):912-7. Abstract

17. Steensma DP, Hoyer JD, Fairbanks VF. Hereditary red blood cell disorders in middle eastern patients. Mayo Clin Proc. 2001 Mar;76(3):285-93. Abstract

18. Ryan K, Bain BJ, Worthington D, et al. Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol. 2010 Apr;149(1):35-49.Full text  Abstract

19. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 Dec 1;106(12):3699-709.Full text  Abstract

20. Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005 Jul;42(3):137-44. Abstract

21. Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced hemolytic anemia - a new paradigm. Transfusion. 2007 Apr;47(4):697-702. Abstract

22. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009 Jan;8(1):73-9. Abstract

23. Yiannakopoulou E. Cephalosporin induced haemolytic anaemia in surgical patients: Systematic review. Rev Clin Pharmacol Pharmacokinet. 2008;22:363-5.

24. Hubl W, Mostbeck B, Hartleb H, et al. Investigation of the pathogenesis of massive hemolysis in a case of Clostridium perfringens septicemia. Ann Hematol. 1993 Sep;67(3):145-7. Abstract

25. Shurin SB, Anderson P, Zollinger J, et al. Pathophysiology of hemolysis in infections with Haemophilus influenzae type b. J Clin Invest. 1986 Apr;77(4):1340-8.Full text  Abstract

26. Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood. 1987 Mar;69(3):820-6.Full text  Abstract

27. Bain BJ. Diagnosis from the blood smear. N Engl J Med. 2005 Aug 4;353(5):498-507. Abstract

28. Marchand A, Galen RS, Van Lente F. The predictive value of serum haptoglobin in hemolytic disease. JAMA. 1980 May 16;243(19):1909-11. Abstract

29. Galen RS. Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med. 1982 Dec;2(4):685-99. Abstract

30. Oppenheim A, Jury CL, Rund D, et al. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet. 1993 Apr;91(3):293-4. Abstract

31. Zecca M, De Stefano P, Nobili B, et al. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001 Jun 15;97(12):3995-7.Full text  Abstract

32. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008 Apr;141(2):149-69. Abstract

33. Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013 Nov;163(3):393-9. Abstract

34. Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015 Apr;14(4):304-13. Abstract

35. Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010 Nov;89(11):1073-80. Abstract

36. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S9-56. Abstract

37. Flores G, Cunningham-Rundles C, Newland AC, et al. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993 Dec;44(4):237-42. Abstract

38. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21;355(12):1233-43.Full text  Abstract

39. Paladio N. Eculizumab for the treatment of paroxysmal nocturnal haemoglobinuria [in Catalan]. Barcelona: Catalan Agency for Health Technology Assessment and Research. 2009.

40. Hassoun H, Palek J. Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Blood Rev. 1996 Sep;10(3):129-47. Abstract

41. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica. 2017 Aug;102(8):1304-13.Full text  Abstract

42. Elyassi AR, Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature. Anesth Prog. 2009 Autumn;56(3):86-91.Full text  Abstract

43. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;(1):CD007798.Full text  Abstract

44. Meyer O, Stahl D, Beckhove P, et al. Pulsed high-dose dexamethasone in chronic autoimmune haemolytic anaemia of warm type. Br J Haematol. 1997 Sep;98(4):860-2. Abstract

45. ClinicalTrials.gov. A study to evaluate efficacy and safety of AG-348 in not regularly transfused adult participants with pyruvate kinase deficiency (PKD). ClinicalTrials.gov Identifier: NCT03548220. Nov 2020 [internet publication].Full text

46. ClinicalTrials.gov. A study evaluating the efficacy and safety of AG-348 in regularly transfused adult participants with pyruvate kinase deficiency (PKD). ClinicalTrials.gov Identifier: NCT03559699. Jan 2022 [internet publication].Full text

47. Röth A, Barcellini W, D'Sa S, et al. Sutimlimab in cold agglutinin disease. N Engl J Med. 2021 Apr 8;384(14):1323-34.Full text  Abstract

48. Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol. 2022 Jan;196(2):336-50.Full text  Abstract

49. Hoffman PC. Immune hemolytic anemia - selected topics. Hematology Am Soc Hematol Educ Program. 2009:80-6.Full text  Abstract

Use of this content is subject to our disclaimer